Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis

Abstract

BackgroundThe purpose of this study was to examine the possible prognostics and clinicopathologic characteristics underlying the BRAFV600E mutation and papillary thyroid carcinoma (PTC) coexisting or in absence of chronic lymphocytic thyroiditis (CLT).MethodsThis study was conducted on 172 patients who had undergone total thyroidectomy or unilateral total thyroidectomy for PTC; the patients were then examined for the BRAFV600E mutation using specimens obtained after their surgery from January 2013 to August 2015.ResultsBRAF mutations were found in 130 of 172 patients (75.6%). CLT was present in 27.9% of patients (48/172). The incidence of the BRAFV600E mutation was significantly increased in the group with no CLT (P = 0.001). The findings of the multivariate analysis pertaining to the coexistence of CLT and PTC showed no significant correlation other than the BRAFV600E mutation. No significant difference was noted in the clinicopathologic factors between the two groups based on the coexistence of CLT in univariate and multivariate analyses.ConclusionsThe BRAFV600E mutation is less frequent in PTC coexisting with CLT presumably because CLT and the BRAFV600E mutation operate independently in the formation and progression of thyroid cancer.

Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience

“…However, the higher frequency could also be attributed to tumors in patients from specific geographic locations and to methodologic differences. Recent studies from eastern Asia demonstrated a higher frequency of approximately 80% for the BRAF V600E mutation in PC, which is consistent with our results (24)(25)(26)(27). Residents in eastern Asia commonly consume seaweeds as a part of their regular diet.…”

“…The use of NGS could be associated with the higher frequency of the BRAF V600E mutation in patients with PC noted in the present study. To date, the frequency of the BRAF V600E mutation in patients with PC has been analyzed using Sanger sequencing (SGS) with FFPE (21,26), SGS with frozen tissue (32,33), pyrosequencing (34) and real-time PCR (27). In the present study, we analyzed FFPE tissue sections obtained from 50 patients with TC using an Illumina Miseq sequencer.…”

Pulmonary Langerhans Cell Histiocytosis

“…Finally, the discovery of mutations involving the MAPK pathway in PLCH has transformed our understanding of the field and firmly established PLCH as a neoplasm. The MAPK mutations found in the PLCH lesions are similar to mutations found in other malignancies such as melanoma, 47 hairy cell leukemia, 48 papillary thyroid cancer, 49 as well as other histiocytic disorders such as ECD. 50 The most common mutation described in PLCH is the BRAF V600E mutation, present in 50% of the patients.…”

Differentiated thyroid cancer theranostics: radioiodine and beyond

“…These play an important part in the tumor dedifferentiation reducing efficacy of RAI. [123][124][125] The extensive mechanism of actions of these mutations are beyond the scope of the review and can be found elsewhere.…”